The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,110.00
Ask: 12,112.00
Change: -186.00 (-1.51%)
Spread: 2.00 (0.017%)
Open: 12,226.00
High: 12,266.00
Low: 12,068.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Pfizer Inc

27 May 2014 11:53

RNS Number : 1179I
Morgan Stanley Capital Services LLC
27 May 2014
 



 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

23 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 COMMON STOCK

 PURCHASES

 156,256

 29.6200 USD

 29.4300 USD

 COMMON STOCK

 SALES

 78,696

 29.6300 USD

 29.4400 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 COMMON STOCK

 CFD

 LONG

 1,500

 29.4826 USD

 COMMON STOCK

 CFD

 LONG

 100

 29.4850 USD

 COMMON STOCK

 CFD

 LONG

 1,000

 29.4862 USD

 COMMON STOCK

 CFD

 LONG

 1,954

 29.4926 USD

 COMMON STOCK

 CFD

 LONG

 287

 29.4926 USD

 COMMON STOCK

 CFD

 LONG

 200

 29.5000 USD

 COMMON STOCK

 CFD

 LONG

 16,100

 29.5161 USD

 COMMON STOCK

 CFD

 LONG

 300

 29.5666 USD

 COMMON STOCK

 CFD

 LONG

 674

 29.5904 USD

 COMMON STOCK

 CFD

 LONG

 7,411

 29.5904 USD

 COMMON STOCK

 CFD

 LONG

 48,870

 29.5960 USD

 COMMON STOCK

 CFD

 LONG

 300

 29.6233 USD

 COMMON STOCK

 CFD

 SHORT

 112

 29.4560 USD

 COMMON STOCK

 CFD

 SHORT

 23

 29.4560 USD

 COMMON STOCK

 CFD

 SHORT

 101

 29.4566 USD

 COMMON STOCK

 CFD

 SHORT

 24

 29.4566 USD

 COMMON STOCK

 CFD

 SHORT

 100

 29.4569 USD

 COMMON STOCK

 CFD

 SHORT

 24

 29.4569 USD

 COMMON STOCK

 CFD

 SHORT

 13

 29.4590 USD

 COMMON STOCK

 CFD

 SHORT

 7

 29.4590 USD

 COMMON STOCK

 CFD

 SHORT

 3,300

 29.4728 USD

 COMMON STOCK

 CFD

 SHORT

 1,409

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 540

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 3,666

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 9,561

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 3,800

 29.4881 USD

 COMMON STOCK

 CFD

 SHORT

 1

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 6

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 45,000

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 3,200

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 2,427

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 373

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 58

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 76

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 7,100

 29.5077 USD

 COMMON STOCK

 CFD

 SHORT

 11,421

 29.5233 USD

 COMMON STOCK

 CFD

 SHORT

 22,500

 29.5322 USD

 COMMON STOCK

 CFD

 SHORT

 4,400

 29.5370 USD

 COMMON STOCK

 CFD

 SHORT

 100

 29.5600 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

27 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDUDUDBGSR
Date   Source Headline
1st Jun 20213:00 pmRNSTotal Voting Rights
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus
21st May 20217:00 amRNSVaxzevria COVID-19 vaccine approved in Japan
18th May 20213:30 pmRNSDirector/PDMR Shareholding
11th May 20212:00 pmRNSResult of AGM
11th May 20211:55 pmRNSShareholders vote in favour of Alexion acquisition
7th May 20217:00 amRNSImfinzi + tremelimumab showed survival in POSEIDON
5th May 20216:30 pmRNSHolding(s) in Company
4th May 20213:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSFarxiga approved in the US for CKD
30th Apr 20217:00 amRNSAZN: First quarter 2021 results
26th Apr 20217:10 amRNSSelumetinib recommended for EU approval in NF1
26th Apr 20217:05 amRNSTagrisso adjuvant receives positive CHMP opinion
26th Apr 20217:00 amRNSNirsevimab Phase III trial met primary endpoint
16th Apr 202112:00 pmRNSUS clearance of proposed acquisition of Alexion
14th Apr 20217:00 amRNSTagrisso approved in China in early lung cancer
12th Apr 20211:00 pmRNSCircular and notice of general meeting
12th Apr 20217:00 amRNSUpdate on Farxiga COVID-19 DARE-19 Phase III trial
1st Apr 20213:00 pmRNSTotal Voting Rights
30th Mar 202112:15 pmRNSNotice of AGM
25th Mar 20213:00 pmRNSDirector/PDMR Shareholding
25th Mar 20217:00 amRNSAZD1222 US Ph3 primary analysis confirms efficacy
22nd Mar 20217:00 amRNSAstraZeneca US vaccine trial met primary endpoint
16th Mar 20217:05 amRNSDivestment of Viela shareholding completed
16th Mar 20217:00 amRNSUS supply agreement for additional AZD7442 doses
9th Mar 20213:00 pmRNSDirector/PDMR Shareholding
4th Mar 20213:00 pmRNSDesignation of EU home member state
3rd Mar 20217:00 amRNSUS court decision favours Symbicort patents
2nd Mar 20217:00 amRNSFurther update on roxadustat US regulatory review
1st Mar 20213:00 pmRNSTotal Voting Rights
22nd Feb 20217:00 amRNSVoluntary withdrawal Imfinzi US bladder indication
17th Feb 20217:00 amRNSLynparza: IDMC recommend early analysis of OlympiA
16th Feb 202111:15 amRNSFiling of Form 20-F with SEC
15th Feb 20213:00 pmRNSDirector/PDMR Shareholding
15th Feb 202111:00 amRNSAnnual Financial Report
11th Feb 20217:01 amRNSAstraZeneca Non-Executive Board changes
11th Feb 20217:00 amRNSAZN: full-year 2020 results
10th Feb 20217:00 amRNSDivestment of Crestor in Europe completed
5th Feb 20217:00 amRNSUpdate on KESTREL Phase III trial for Imfinzi
4th Feb 20217:00 amRNSForxiga approved in China for heart failure
1st Feb 20213:00 pmRNSTotal Voting Rights
1st Feb 202112:15 pmRNSAstraZeneca agrees to divest Viela shareholding
1st Feb 20217:00 amRNSCOVID-19 vaccine authorised for use by the EU
29th Jan 20213:16 pmRNSCOVID-19 vaccine receives positive opinion in EU

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.